One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal ...

Initial funding of USD 29 million to support development of Basilea’s clinical stage first-in-class antifungals, fosmanogepix ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. Patients infected with ...

A HAIR hobbyist has revealed a simple yet effective hack that will give you a professional looking bouncy blow dry. Abigail Lin shared a video of her hair tutorial and it has since gone viral with ...

Candida albicans Cdr1 pumps azole antifungal drugs out of the cell, driving drug resistance. Here, the authors determine the mechanism of Cdr1-mediated fluconazole resistance and milbemycin oxime ...

Initial funding of USD 29 million to support development of Basilea's clinical stage first-in-class antifungals, fosmanogepix and BAL2062 -- ...

In continuing this partnership through an OTA, we will be leveraging our strong portfolio and the capabilities of our organization to develop urgently needed novel antifungals and antibacterials. We ...

(RTTNews) - Basilea Pharmaceutica Ltd said it entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to develop novel antifungals and antibacterials.

Since mid-2002, two new antifungal drugs — voriconazole, a third-generation azole, and caspofungin, a member of a new class of drugs called echinocandins — have been marketed in Spain.

The Spanish COPD guidelines recommend treatment of the mixed COPD–asthma phenotype with ICS and a long-acting bronchodilator (LABD) as a first option to improve lung function, respiratory ...